CD86 and neoplasm: Furthermore, increased DC expression of costimulatory CD80/CD86 was observed in the TME, consistent with the substantial increase in the tumor CD8+ T cells in SAProsome-3–treated mice (Fig. 4e and Supplementary Fig. S20).